RVNC

Insider Trades

Name	Value	Action	Price	Current Price
Hollander DavidCMO & Global Therapeutics Lead $16k3.9k shares SellNov 18, 2024 $4.17 --

Trade RVNC

About Revance Therapeutics, Inc.

Revance Therapeutics, Inc. is a biotechnology company specializing in the research, manufacturing, and marketing of neuromodulators for diverse aesthetic and therapeutic uses across both domestic and international markets. The company's leading product candidate, DaxibotulinumtoxinA for injection, has concluded Phase III clinical evaluations for treating glabellar (frown) lines and cervical dystonia. This same drug is currently in Phase II clinical trials for addressing upper facial lines, moderate to severe dynamic forehead lines, and moderate to severe lateral canthal lines, following the successful completion of its Phase II trials for adult upper limb spasticity and plantar fasciitis. Beyond this, Revance is conducting preclinical studies for DaxibotulinumtoxinA as a potential migraine treatment and is developing a topical version for various indications. The company is also developing OnabotulinumtoxinA, intended as a biosimilar to BOTOX. A collaborative and licensing partnership with Viatris Inc. facilitates the development, manufacturing, and commercialization of onabotulinumtoxinA. Initially established in 1999 as Essentia Biosystems, Inc., the company officially rebranded as Revance Therapeutics, Inc. in April 2005 and maintains its corporate headquarters in Nashville, Tennessee.

CEO: Mark J. Foley
IPO Date: Feb 6, 2014

Market Data

Open: $3.65
High: $3.65
Low: $3.65
Volume: 0
Avg Volume: 3M
52W High: $7.56
52W Low: $2.30

Valuation

Market Cap: $381M
Enterprise Value: $722M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-223M
Revenue: $234M
Net Income: $-324M
Cash: $137M
Debt: $478M

Events

EarningsNov 5